Pharmacotherapy of ADHD in Adults

Abstract

Besides psychosocial interventions, like psychoeducation and specific psychotherapeutic treatments, e.g., cognitive-behavioral therapy, pharmacological treatments present a key element within the overall therapeutic concept of attention-deficit hyperactivity disorder (ADHD) in children, adolescents, and adults. Currently, three different pharmacological agents are approved by federal agencies in Germany for the treatment of ADHD in adults. As stimulants, delayed release methylphenidate and lisdexamfetamine can be prescribed. Efficacy and tolerance of both agents can be considered as good. Alternatively, atomoxetine can be prescribed, which does not belong to the stimulants and whose efficacy and tolerance can be considered as good as well.